Get the Stockscreener App
1.08
1.82%
-0.02
After Hours:
1.09
0.01
+0.93%
Connect Biopharma Holdings Ltd stock is traded at $1.08, with a volume of 802.62K.
It is down -1.82% in the last 24 hours and down -55.92% over the past month.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
See More
Previous Close:
$1.10
Open:
$1.09
24h Volume:
802.62K
Relative Volume:
0.82
Market Cap:
$68.01M
Revenue:
$233.00K
Net Income/Loss:
$-64.61M
P/E Ratio:
-0.9362
EPS:
-1.1536
Net Cash Flow:
$-58.32M
1W Performance:
-15.62%
1M Performance:
-55.92%
6M Performance:
-67.86%
1Y Performance:
-36.09%
1-Day Range:
$1.06
$1.12
1-Week Range:
$1.06
$1.33
52-Week Range:
$1.06
$3.82
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Name
Connect Biopharma Holdings Ltd
Sector
Industry
Phone
858-727-1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.08 | 68.01M | 233.00K | -64.61M | -58.32M | -1.1536 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Lake Street | Buy |
| Oct-31-25 | Initiated | BTIG Research | Buy |
| Jun-12-25 | Initiated | H.C. Wainwright | Buy |
| Mar-04-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Apr-13-21 | Initiated | Piper Sandler | Overweight |
| Apr-13-21 | Initiated | SVB Leerink | Outperform |
View All
Connect Biopharma Holdings Ltd Stock (CNTB) Latest News
Connect Biopharma Holdings Limited (CNTB) Stock Price, News, Quote & History - ca.finance.yahoo.com
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView
H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 - Investing.com
Connect Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co. - Moomoo
Connect Biopharma Holdings Limited (CNTB) Stock Price | Live Quotes & Charts | NASDAQ - stockstotrade.com
Canaccord cuts Connect Biopharma stock price target on trial miss - Investing.com
Connect Biopharma (NASDAQ:CNTB) Given "Buy" Rating at BTIG Research - MarketBeat
FEV1 well done, will FDA Connect the phase II asthma dots? - BioWorld News
Why Is Connect Biopharma Stock Trading Lower on Tuesday? - Benzinga
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance - Yahoo Finance
Why is Connect Biopharma stock plunging 33% today? - Investing.com
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com India
Connect Biopharma reports phase 2 asthma trial results By Investing.com - Investing.com India
Connect Biopharma (CNTB) asthma trial cuts failures 66% but misses main goal - Stock Titan
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation - globenewswire.com
H.C. Wainwright reiterates Connect Biopharma stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $7 - Moomoo
H.C. Wainwright reiterates Connect Biopharma stock rating at buy - Investing.com
CNTB News | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
A Sept. 15 live webcast will feature Connect Biopharma management - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - simplywall.st
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com South Africa
Will Connect Biopharma (CNTB) Breathe Easy After Seabreeze Trials? - RTTNews
Connect Biopharma Holdings Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Issues Pessimistic Forecast for CNTB Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A - Stock Titan
Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake - Stock Titan
Connect Biopharma Holdings Ltd expected to post a loss of 21 cents a shareEarnings Preview - TradingView
BTIG Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Connect Biopharma Holdings earnings beat by ¥0.33, revenue topped estimates - Investing.com Canada
Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates - Investing.com
Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million - scanx.trade
Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026 - Stock Titan
Connect Biopharma Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M - Stock Titan
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Connect Biopharma Holdings Ltd (CNTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Connect Biopharma Holdings Ltd (CNTB) Stock News Today - TradingKey
Connect Biopharma (CNTB) Projected to Release Earnings on Wednesday - MarketBeat
Connect Biopharma (CNTB) Slides 3.35% to $2.02: Support and Resistance Levels in FocusMA Cross Alert - careplusvn.com
ADAR1 Capital Management LLC Invests $1.95 Million in Connect Biopharma Holdings Limited Sponsored ADR $CNTB - MarketBeat
Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNTB|Connect Biopharma Holdings Ltd|Price:2.110|Chg%:-0.030 - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Balance Sheet - TradingKey
Connect Biopharma Holdings Ltd Stock (CNTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):